Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
We report the case of a 56-year old male with severe plaque psoriasis that was successfully treated with ixekizumab, a new anti interleukin (IL)-17 monoclonal antibody. During the first months of treatment he developed a lentiginous eruption in the sites of rapidly resolving plaques. Biopsy and immu...
Main Authors: | Pablo Santa María, Fernando Valenzuela, Claudia Morales, Raul De la Fuente, Roberto Cullen |
---|---|
Format: | Article |
Language: | English |
Published: |
PAGEPress Publications
2017-10-01
|
Series: | Dermatology Reports |
Subjects: | |
Online Access: | http://www.pagepress.org/journals/index.php/dr/article/view/7079 |
Similar Items
-
Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01) -
Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01) -
Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020-03-01) -
Ixekizumab May Improve Renal Function in Psoriasis
by: Giuseppe Fabrizio Amoruso, et al.
Published: (2021-05-01) -
Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)